<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>63(7)</volume><submitter>Alberge JB</submitter><pubmed_abstract>The International Myeloma Working Group recently fully incorporated &lt;sup>18&lt;/sup>F-FDG PET into multiple myeloma (MM) diagnosis and response evaluation. Moreover, a few studies demonstrated the prognostic value of several biomarkers extracted from this imaging at baseline. Before these &lt;sup>18&lt;/sup>F-FDG PET biomarkers could be fully endorsed as risk classifiers by the hematologist community, further characterization of underlying molecular aspects was necessary. &lt;b>Methods:&lt;/b> Reported prognostic biomarkers (&lt;sup>18&lt;/sup>F-FDG avidity, SUV&lt;sub>max&lt;/sub>, number of focal lesions, presence of paramedullary disease [PMD] or extramedullary disease) were extracted from &lt;sup>18&lt;/sup>F-FDG PET imaging at baseline in a group of 139 patients from CASSIOPET, a companion study of the CASSIOPEIA coh</pubmed_abstract><journal>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</journal><pagination>1008-1013</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9258580</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Molecular Signature of &lt;sup>18&lt;/sup>F-FDG PET Biomarkers in Newly Diagnosed Multiple Myeloma Patients: A Genome-Wide Transcriptome Analysis from the CASSIOPET Study.</pubmed_title><pmcid>PMC9258580</pmcid><pubmed_authors>Touzeau C</pubmed_authors><pubmed_authors>Cherel M</pubmed_authors><pubmed_authors>Wuilleme S</pubmed_authors><pubmed_authors>Corre J</pubmed_authors><pubmed_authors>Jamet B</pubmed_authors><pubmed_authors>Caillon H</pubmed_authors><pubmed_authors>Bailly C</pubmed_authors><pubmed_authors>Moreau P</pubmed_authors><pubmed_authors>Bene MC</pubmed_authors><pubmed_authors>Kampfenkel T</pubmed_authors><pubmed_authors>Bodet-Milin C</pubmed_authors><pubmed_authors>Carlier T</pubmed_authors><pubmed_authors>Alberge JB</pubmed_authors><pubmed_authors>Sonneveld P</pubmed_authors><pubmed_authors>Avet-Loiseau H</pubmed_authors><pubmed_authors>van Duin M</pubmed_authors><pubmed_authors>Kraeber-Bodere F</pubmed_authors><pubmed_authors>Magrangeas F</pubmed_authors><pubmed_authors>Minvielle S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Molecular Signature of &lt;sup>18&lt;/sup>F-FDG PET Biomarkers in Newly Diagnosed Multiple Myeloma Patients: A Genome-Wide Transcriptome Analysis from the CASSIOPET Study.</name><description>The International Myeloma Working Group recently fully incorporated &lt;sup>18&lt;/sup>F-FDG PET into multiple myeloma (MM) diagnosis and response evaluation. Moreover, a few studies demonstrated the prognostic value of several biomarkers extracted from this imaging at baseline. Before these &lt;sup>18&lt;/sup>F-FDG PET biomarkers could be fully endorsed as risk classifiers by the hematologist community, further characterization of underlying molecular aspects was necessary. &lt;b>Methods:&lt;/b> Reported prognostic biomarkers (&lt;sup>18&lt;/sup>F-FDG avidity, SUV&lt;sub>max&lt;/sub>, number of focal lesions, presence of paramedullary disease [PMD] or extramedullary disease) were extracted from &lt;sup>18&lt;/sup>F-FDG PET imaging at baseline in a group of 139 patients from CASSIOPET, a companion study of the CASSIOPEIA coh</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Jul</publication><modification>2025-04-22T10:12:25.514Z</modification><creation>2025-04-05T23:28:19.327Z</creation></dates><accession>S-EPMC9258580</accession><cross_references><pubmed>35086897</pubmed><doi>10.2967/jnumed.121.262884</doi></cross_references></HashMap>